An Early Phase 1 interventional study of rosuvastatin and placebo in Atherosclerosis and Inflammatory Activity in Carotid Arteries, sponsored by AstraZeneca. Completed at 1 site in Sweden. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-06-30.
Sponsored by AstraZeneca · Early Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing rosuvastatin in Atherosclerosis — 1 open to participants now, 2 under way, 1 of them phase 3. rosuvastatin · Atherosclerosis.
Among the 25 studies testing rosuvastatin in Atherosclerosis, this one is the 13th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2007, is one of 3 in phase 1, and was the 8th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →1 of the 25 studies testing rosuvastatin in Atherosclerosis is open now, in 1 country. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 30–60
By country, each count listing its studies:
rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →
Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 74 is below the median of 100 across 881 interventional studies indexed under Atherosclerosis.
Median enrollment 77 across the 24 interventional studies. Of the 19 that completed or were terminated, 5 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 25 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
21 studies in Atherosclerosis by AstraZeneca: 1 open now, 2 under way, 2 of them phase 3. Of 19 finished, 4 (21%) have results posted.
Among the 21 studies in Atherosclerosis by AstraZeneca, this one is the 9th largest by planned enrollment of the 14 interventional ones that give a count, is one of 6 that started in 2007, is one of 7 in phase 1, and was the 7th registered.
AstraZeneca’s Atherosclerosis studies by the year they started, since 2004.
1 of the studies testing rosuvastatin in Atherosclerosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05850091Massachusetts General HospitalPolygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies testing rosuvastatin in Atherosclerosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 21 in Atherosclerosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary aim of this study is to investigate the effect of 40 mg dose of rosuvastatin on carotid plaque inflammation measured with MRI and PET scanning, to evaluate whether these techniques are promising for future proof of principle studies. A number of patients will receive placebo as a control.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: rosuvastatin
Drug: placebo
40 mg, tablet, once daily for 3 months.
Also known as: Crestor
40 mg, tablet, once daily for 3 months
Comparison between the active and the placebo group regarding changes in MRI contrast enhancement in terms of the transfer constant (Ktrans) for the carotid region
Time frame: MRI scan at enrolment visit and within group after 3 months.
Comparison between the active and the placebo group regarding changes in MRI contrast enhancement measured as fractional plasma volume (Vp) and changes in 18FDG uptake in terms of standardised uptake value (SUV), respectively
Time frame: MRI scan at enrolment visit and within group after 3 months. 18FDG at randomisation visit (baseline) and within group after 3 months treatment.
Change in carotid MRI contrast enhancement in terms of Ktrans and Vp.
Time frame: At enrolment visit and within group after 3 months treatment.
Change in 18FDG uptake in terms of SUV.
Time frame: At randomisation visit (baseline) and within group after 3 months treatment.
The record gives a start of Dec 2007 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rosuvastatin